Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Qing Xia
Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Oncogenes and Related Genes
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
20
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Sintilimab Plus Docetaxel as Second-Line Therapy of Advanced Non-Small Cell Lung Cancer Without Targetable Mutations: A Phase II Efficacy and Biomarker Study
Number of pages: 28
Posted: 25 Apr 2022
Yongchang Zhang
,
Lianxi Song
,
Liang Zeng
,
Yi Xiong
,
Li Liu
,
Chunhua Zhou
,
Haiyan Yang
,
Zhan Wang
, Qing Xia,
Wenjuan Jiang
,
Qinqin Xu
and
Nong Yang
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Oncogenes and Related Genes, Central South University - Hunan Cancer Hospital, Qinghai Provincial People's Hospital - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads
20
(1,459,862)
View PDF
Download
Abstract:
Sintilimab plus docetaxel, NSCLC, CTC-PD-L1, multiplex immunofluorescence
Feedback